Mont. Code Ann. § 50-17-102
Definitions
(1)En. Sec. 2, Ch. 197, L. 1967; amd. Sec. 28, Ch. 349, L. 1974; Sec. 69-4102, R.C.M. 1947; (2), (3)En. Sec. 25, Ch. 197, L. 1967; Sec. 69-4302, R.C.M. 1947; R.C.M. 1947, 69-4102(2), 69-4302; amd. Sec. 2, Ch. 61, L. 1985; amd. Sec. 112, Ch. 418, L. 1995; amd. Sec. 289, Ch. 546, L. 1995; amd. Sec. 1, Ch. 190, L. 2001; amd. Sec. 1, Ch. 400, L. 2017; amd. Sec. 9, Ch. 602, L. 2023.
As used in this chapter, unless the context clearly indicates otherwise, the following definitions apply:
- (1) "Acute heart attack" means a heart attack that involves a prolonged period of blocked blood supply, affects a large area of the heart, and is measured by an elevation of the ST segment of an electrocardiogram.
- (2) "Approved course of treatment" means a course of treatment for tuberculosis that includes medical treatment prescribed by a physician and consistent with accepted medical standards, as well as appropriate followup to ensure public health and safety as set out in the rules of the department.
- (3) "Critical access hospital" has the meaning provided in 50-5-101.
- (4) "Department" means the department of public health and human services provided for in 2-15-2201.
- (5) "Emergency medical service" has the meaning provided in 50-6-302.
- (6) "Hospital" has the meaning provided in 50-5-101 and includes a rural emergency hospital as defined in 50-5-101.
- (7) "Local board" means a city, county, city-county, or district board of health.
- (8) "Receiving hospital" means a hospital capable of performing coronary revascularization for a patient suffering an acute heart attack.
- (9) "Treatment location" or "location" means a hospital or other place designated by a local health officer where the person diagnosed with tuberculosis must remain to be available for an approved course of treatment.
(10)
- (a) "Tuberculosis" means a disease caused by mycobacterium tuberculosis or mycobacterium tuberculosis complex.
- (b) The term does not include infection by mycobacterium bovis in a nonpulmonary site that is a result of instillation of bacille calmette-guerin as part of cancer therapy.
History: (1)En. Sec. 2, Ch. 197, L. 1967; amd. Sec. 28, Ch. 349, L. 1974; Sec. 69-4102, R.C.M. 1947; (2), (3)En. Sec. 25, Ch. 197, L. 1967; Sec. 69-4302, R.C.M. 1947; R.C.M. 1947, 69-4102(2), 69-4302; amd. Sec. 2, Ch. 61, L. 1985; amd. Sec. 112, Ch. 418, L. 1995; amd. Sec. 289, Ch. 546, L. 1995; amd. Sec. 1, Ch. 190, L. 2001; amd. Sec. 1, Ch. 400, L. 2017; amd. Sec. 9, Ch. 602, L. 2023.